A Phase IB/II Clinical Study to Assess the Safety and Preliminary Efficacy of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs CM 313 (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
- 31 Jan 2025 New trial record